Drug Delivery to the Brain
A special issue of Pharmaceutics (ISSN 1999-4923).
Deadline for manuscript submissions: closed (31 October 2019) | Viewed by 83842
Special Issue Editor
Interests: blood–brain barrier; drug delivery; hypoxia; intracellular signaling; ischemic stroke; molecular pharmacology; pharmacokinetics; transporters
Special Issue Information
Dear colleagues,
The blood–brain barrier (BBB) and blood–cerebrospinal fluid (BCSF) barriers are critical determinants of CNS homeostasis. Additionally, the BBB and BCSF barriers are formidable obstacles to effective drug delivery to the brain. These barrier tissues are characterized by highly limited paracellular transport and expression of numerous efflux transporters that greatly restrict the ability of small and large molecule drugs to access therapeutic targets in brain tissue. Over the past many years, multiple approaches have been developed in an effort to circumvent brain barriers and improve the pharmacotherapy of neurological diseases. In this Issue of Pharmaceutics, critical considerations for drug permeation across brain barriers will be discussed, and state-of-the-art current and future strategies for effective CNS drug delivery will be rigorously reviewed. Additionally, remaining challenges for the treatment of neurological diseases will be outlined with an emphasis on how solutions to such issues can be provided via cutting edge preclinical and clinical studies.
Dr. Patrick T. Ronaldson
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- blood–brain barrier
- blood–cerebrospinal fluid barrier
- drug delivery
- nanotechnology
- neurovascular unit
- pharmacokinetics
- transcytosis
- transporters
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.